MedTrace Logo

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

NCT00883688 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-08-26

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if the combination of Avastin (bevacizumab) and Tykerb (lapatinib) can help to control ependymoma in pediatric patients. The safety of this drug combination will also be studied.

Conditions

Interventions

DRUG

Bevacizumab

10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week "study cycle").

DRUG

Lapatinib

Pills of 700 mg/m\^2/dose given orally 2 times each day.

Sponsors & Collaborators

  • CERN Foundation - Collaborative Ependymoma Research Network

    collaborator NETWORK

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Michael E. Rytting, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00883688 on ClinicalTrials.gov